Drugs / NNC0705-0001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07029568 | Jun → Nov 2025 | chronic kidney disease | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC0705-0001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029568 ↗ |
| Route | Oral | “NNC0705-0001 will be administered orally.” NCT07029568 ↗ |